A Phase I, Multi-Center, Dose-Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of AV-412 Administered Orally Three Times Weekly to Subjects With Advanced Solid Tumors

The Epidermal Growth Factor Receptor (EGFR) is a validated target for the treatment of cancer, and agents targeting EGFR such as erlotinib (Tarceva®) are approved by the FDA for treatment of various solid tumors. AV-412 is a novel inhibitor of the EGFR-tyrosine kinase, with added activity against Her2 and other oncogenic kinases. Based on evidence of preclinical activity in various solid tumors, AV-412 is being developed as a possible novel treatment for cancer in humans.
PURPOSE: The purpose of this study is to test the safety and tolerability of AV-412, and determine the maximum tolerated dose of AV-412 when administered orally three times weekly.

Start Date01 Oct 2007

Sponsor / Collaborator

AVEO Pharmaceuticals, Inc.

NCT00381654 / TerminatedPhase 1

A Phase 1, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily Oral Administration of AV-412 in Patients With Refractory or Relapsed Solid Tumor Malignancies

AV-412 is a new oral therapy developed to inhibit the growth of solid tumors in patients who have not responded to standard therapy or surgical interventions, or who have experienced relapse. This study will test the safety of AV-412 and determine the maximum tolerated dose for the treatment of solid tumors.

Start Date01 Oct 2006

Sponsor / Collaborator

AVEO Pharmaceuticals, Inc.

100 Clinical Results associated with MP-412

100 Translational Medicine associated with MP-412

100 Patents (Medical) associated with MP-412

Literatures (Medical) associated with MP-412

01 Jan 2010·IDrugs : the investigational drugs journal

AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 2.

Article

Author: Walker, Karen ; Padhiar, Meenal

The 21st international symposium of the American Association for Cancer Research (AACR), the NCI and the European Organization for Research and Treatment of Cancer (EORTC), held in Boston, included topics covering the development of therapeutics and molecular targets in the field of cancer research. This conference report highlights selected presentations on the development of novel drugs for cancer. Investigational drugs discussed include RO-506876 (F Hoffmann-La Roche Ltd), GDC-0980 (Genentech Inc), EMD-1214063 and EMD-1204831 (Merck Serono SA), AR-mTOR01 and AR-mTOR-26 (Array BioPharma Inc), GSK-2126458 (GlaxoSmithKline plc), EXEL-1415 and EXEL-2008 (Exelixis Inc), FP-1039 (FivePrime Therapeutics Inc), and AV-412 (AVEO Pharmaceuticals Inc).

100 Deals associated with MP-412

External Link

KEGG	Wiki	ATC	Drug Bank
-	MP-412	-	DB06021

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced cancer	Phase 2	US	AVEO Pharmaceuticals, Inc.	01 Oct 2007
Advanced Malignant Solid Neoplasm	Phase 2	US	AVEO Pharmaceuticals, Inc.	01 Oct 2007
Refractory Cancer	Phase 2	US	AVEO Pharmaceuticals, Inc.	01 Oct 2007
Refractory Malignant Solid Neoplasm	Phase 2	AR	AVEO Pharmaceuticals, Inc.	01 Oct 2006
Refractory Malignant Solid Neoplasm	Phase 2	US	AVEO Pharmaceuticals, Inc.	01 Oct 2006
Neoplasms	Phase 2	-	Mitsubishi Tanabe Pharma Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2010	Phase 1	HR-positive/HER2-low Solid Tumors	36	AV-412	(ljuyfqlctw) = hhdvenqjli mwbbasrdmc (nzkamxqhku ) View more	-	20 May 2010

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis